|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q3 FY2020
As of Sep 30, 2020
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q1 FY2021
As of Mar 31, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2020
As of Mar 31, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current asset: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Due from Related Party | ||||||||||||||||||||
| Prepaid Expenses | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Right-of-use asset | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts Payable | ||||||||||||||||||||
| Promissory note | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| Amount due to a director | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Total Long Term Liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Preferred stock, 10,000,000 shares authorized, $0.001 par value, 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||||||||||||||||||||
| Common stock, 300,000,000 shares authorized, $0.001 par value, 14,706,513 and 14,706,513 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Common stock to be issued | ||||||||||||||||||||
| Common stock to be issued, $0.001 par value, 2,000,000 and 0 shares as of December 31, 2023 and December 31, 2022, respectively | ||||||||||||||||||||
| Common stock to be issued, $0.001 par value, 2,000,000 and 0 shares as of March 31, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Stockholders’ deficit | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
Loading...
